TXNRD1 and hepatocellular carcinoma: With respect to TXNRD1, the fourth LMAG identified in the study, inhibiting the NRF2/TXNRD1 signaling axis has been demonstrated as an efficient approach to restrain HCC growth, and combination therapy with sorafenib and NRF2/TXNRD1 inhibitors may be a promising strategy for personalized HCC treatment (Gao et al., 2020).